Dr. Debu Tripathy on the CDK4/6 Inhibitor PD 0332991

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses a phase II trial that examined the oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor PD 0332991 (991) as a first-line therapy for women with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.

In general, CDKs are regulated by cyclins and facilitate the cell cycle. The rationale for the trial was based on the observed overproduction of cyclin D in patients with ER-positive breast cancer, Tripathy explains. In general, cyclin D is encoded by the CCND1 gene and interacts with CDK 4 and 6 to moderate cell cycle progression.

In the trial, 165 patients were randomized 1:1 to receive letrozole alone or in combination with PD 0332991. Patients were further stratified into two parts based on CCND1 amplification and/or a loss of p16 expression, both indicators of cyclin D abnormality.

The addition of PD 0332991 to letrozole resulted in improved progression-free survival (PFS) between all subgroups of the trial. The median PFS benefit for the combination was 26.1 months compared to 7.5 months for letrozole alone (HR = 0.37; P < .001).

Tripathy notes that toxicities with PD 0332991 did not appear to be significantly greater. The most common adverse event was uncomplicated neutropenia, which was easily managed in the trial.

A randomized phase III trial examining PD 0332991 is scheduled.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD